Cynthia T. Mazareas

Cynthia Mazareas brings more than 25 years of experience and a passion for medical and scientific innovation to her role as a trusted adviser to companies in the life sciences, medical device and biopharmaceutical industries. She provides ongoing, strategic business counsel to boards, management teams and in-house counsel, representing high-growth private and public companies in day-to-day corporate matters and helping these companies navigate through complex business transactions. 

In addition to advising clients on a wide range of corporate matters, Ms. Mazareas has significant experience counseling public and private companies in venture capital and public securities offerings including IPOs, follow-on offerings, PIPEs, ATMs and registered direct offerings, as well as matters of corporate governance and Securities and Exchange Commission, NASDAQ and Sarbanes-Oxley compliance.

Ms. Mazareas has counseled a range of public life sciences companies throughout all stages of growth, including Achillion Pharmaceuticals, Agios Pharmaceuticals, Arsanis, AVEO Pharmaceuticals, Curis, IMARA, Infinity Pharmaceuticals, Schrödinger, Syros Pharmaceuticals and Translate Bio. Her private company clients have included Auron Therapeutics and Tvardi Therapeutics. 

Clients rely on her combination of industry knowledge, legal experience and business acumen. One told Best Lawyers that she is “amazing” and gives “great practical advice.” Another told Chambers and Partners, “I think very highly of Cynthia Mazareas, in life sciences in particular. She’s someone who truly does live the life of her clients. She’s been doing this for a long time and she understands a great deal of the challenges that smaller companies face and is very adept at trying to help folks work through the types of challenges encountered by those companies.”

Ms. Mazareas’s involvement with the biopharmaceutical industry predates her legal career: she began her professional life in healthcare, a background that gives her insight into the real-world concerns that shape the landscape for such companies.

Community Involvement

Ms. Mazareas’ engagement with the life sciences industry extends to her community involvement. She serves on the Board of Directors for Life Science Cares, a nonprofit organization that brings together companies in the life sciences industry to eliminate the impact of poverty in the greater Boston area, and chairs the organization’s Nominating and Governance Committee. She was also a member of the Board of Directors of Prize4Life, a nonprofit that works to find treatments and cures for ALS. She and her husband received the Courage Award from Prize4Life in 2014.

Ms. Mazareas has also served as a member of the Board of Trustees of Shore Country Day School and as chair of its Diversity Committee and a member of its Committee on Trustees.

Professional Activities

Ms. Mazareas is an author and frequent speaker on corporate transactions, governance and other matters relating to life sciences and biotechnology companies.

She is a member of the Massachusetts Biotechnology Council, the Massachusetts Bar Association and the Boston Bar Association. She also plays an active role at WilmerHale as a member of the firm's Women's Leadership Initiative and the Hiring Committee.

  • Cynthia Mazareas Named Among the 2019 and 2020 Best Lawyers in America®

    Cynthia Mazareas is recognized by her peers as an outstanding lawyer in the areas of biotechnology and life sciences.

    August 15, 2019
    Read More
  • LMG Life Sciences Recognizes Cynthia Mazareas as US Rising Transactional Star

    In its annual recognition of top law firms, lawyers and in-house counsel in the life sciences industry, LMG Life Sciences named Cynthia Mazareas to its 2017 award shortlist.

    July 20, 2017
    Read More
  • Cynthia Mazareas Joins Life Science Cares Board

    Cynthia Mazareas joined the board of directors of Life Science Cares, an organization seeking to eliminate the impact of poverty in the greater Boston-area through collective effort.

    June 6, 2018
    Read More



    • Represents a wide range of privately held life science companies in formation, early-stage, bridge, mezzanine and cross-over venture capital transactions
    • Represents a wide range of publicly traded life science companies in IPOs and underwritten follow-on offerings, as well as in the establishment of "at-the-market" sales arrangements, PIPEs, registered direct offerings and strategic equity transactions

    • Schrödinger in its initial public and its prior Series E financing round led by WuXi AppTec and the Bill & Melinda Gates Foundation
    • IMARA in its initial public offering
    • Arsanis in its initial public offering and subsequent merger with X4 Pharmaceuticals
    • Translate Bio in its initial public offering and subsequent PIPE and follow-on offerings
    • Agios Pharmaceuticals in its initial public offering, side-by-side strategic private placements and numerous subsequent follow-on offerings 
    • Syros Pharmaceuticals in its initial public offering and subsequent PIPE, follow-on offerings and side-by-side strategic private placements 
    • Achillion Pharmaceuticals in its strategic equity investment by Johnson & Johnson Innovation-JJDC, Inc., its subsequent secondary underwritten public offering, and its registered direct offering with a privately-owned hedge fund sponsor
    • Infinity Pharmaceuticals in its reverse merger/going public transaction, its royalty sale, its strategic equity transactions with Purdue Pharma, and Purdue Pharma's subsequent secondary underwritten public offering 
    • Curis, in its follow-on offerings and royalty sales
    • Tvardi Therapeutics in a Series A financing
    • BlinkBio in Series A and B financings 
    • KEW, a comprehensive genomic profiling company, in Series A, B and C financings and bridge financing


Insights & News


  • Education

    • JD, Georgetown University Law Center, 1993

    • BS, Boston University, 1985

  • Admissions

    • Massachusetts